... Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz. Shares of Tarrytown, N.Y.-based Regeneron closed at $276.41 on Thursday and have climbed more than 62 percent this year. U.S.-traded shares of ...
http://www.pharmpro.com/news/2013/11/sanofi-regeneron-arthritis-drug-fares-well-study
http://www.pharmpro.com/news/2013/11/sanofi-regeneron-arthritis-drug-fares-well-study
No comments:
Post a Comment